These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27879426)

  • 1. The successful concurrent use of two long-acting depot antipsychotics in a patient with treatment-resistant schizophrenia and history of serious violence: a case report.
    Lenardon A; Ahmed M; Harfield KL; Das M
    Australas Psychiatry; 2017 Apr; 25(2):181-184. PubMed ID: 27879426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.
    Suzuki T; Remington G; Arenovich T; Uchida H; Agid O; Graff-Guerrero A; Mamo DC
    Br J Psychiatry; 2011 Oct; 199(4):275-80. PubMed ID: 22187729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital.
    Hotham JE; Simpson PJ; Brooman-White RS; Basu A; Ross CC; Humphreys SA; Larkin F; Gupta N; Das M
    CNS Spectr; 2014 Oct; 19(5):403-10. PubMed ID: 24284256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Naturalistic, retrospective comparison between second-generation antipsychotics and depot neuroleptics in patients affected by schizophrenia.
    Marchiaro L; Rocca P; LeNoci F; Longo P; Montemagni C; Rigazzi C; Bogetto F
    J Clin Psychiatry; 2005 Nov; 66(11):1423-31. PubMed ID: 16420080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
    Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
    Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.
    Valenstein M; Copeland LA; Owen R; Blow FC; Visnic S
    J Clin Psychiatry; 2001 Jul; 62(7):545-51. PubMed ID: 11488366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.
    Ascher-Svanum H; Peng X; Faries D; Montgomery W; Haddad PM
    BMC Psychiatry; 2009 Jul; 9():46. PubMed ID: 19640279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.
    Schreiner A; Bergmans P; Cherubin P; Keim S; Llorca PM; Cosar B; Petralia A; Corrivetti G; Hargarter L
    J Psychopharmacol; 2015 Aug; 29(8):910-22. PubMed ID: 25999398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
    Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
    Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.